NASDAQ:QCLS Mymd Pharmaceuticals (QCLS) Stock Price, News & Analysis $2.87 +0.12 (+4.36%) As of 02:05 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesSEC FilingsTrendsBuy This Stock About Mymd Pharmaceuticals Stock (NASDAQ:QCLS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Mymd Pharmaceuticals alerts:Sign Up Key Stats Today's Range$2.78▼$2.9650-Day Range$2.51▼$4.7652-Week Range$2.50▼$12.24Volume145,363 shsAverage Volume698,134 shsMarket Capitalization$11.97 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview MyMD Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for immune-related and other serious diseases. The company has worked on product candidates designed to address conditions involving inflammation, immune system dysfunction, and age-related disease processes. The company’s pipeline has included drug development programs in areas such as autoimmune and inflammatory disorders, with an emphasis on advancing compounds through preclinical and clinical evaluation. MyMD Pharmaceuticals is based in the United States and has operated as a research-driven biotechnology company centered on bringing new therapeutic options to market. Because company details can change over time and reliable, up-to-date information on leadership and current geographic operations is limited, this description is intentionally brief and limited to broadly verifiable business information.AI Generated. May Contain Errors. Read More Mymd Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks2nd Percentile Overall ScoreQCLS MarketRank™: Mymd Pharmaceuticals scored higher than 2% of companies evaluated by MarketBeat, and ranked 583rd out of 592 stocks in the technology sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingMymd Pharmaceuticals has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageMymd Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about Mymd Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Mymd Pharmaceuticals is -0.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Mymd Pharmaceuticals is -0.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMymd Pharmaceuticals has a P/B Ratio of 0.56. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted38.70% of the float of Mymd Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverMymd Pharmaceuticals has a short interest ratio ("days to cover") of 7.13.Change versus previous monthShort interest in Mymd Pharmaceuticals has recently increased by 4.59%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMymd Pharmaceuticals does not currently pay a dividend.Dividend GrowthMymd Pharmaceuticals does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Mymd Pharmaceuticals this week, compared to 0 articles on an average week.MarketBeat Follows1 people have added Mymd Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Mymd Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders0.86% of the stock of Mymd Pharmaceuticals is held by insiders.Percentage Held by Institutions9.64% of the stock of Mymd Pharmaceuticals is held by institutions.Read more about Mymd Pharmaceuticals' insider trading history. Receive QCLS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mymd Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. QCLS Stock News HeadlinesQ/C Technologies Appoints Veteran Silicon Photonics Engineer Yossef Ehrlichman as Founding Manager, Photonic Integrated Circuit (PIC) Development4 hours ago | globenewswire.comQ/C Technologies Relocates Headquarters to San Francisco in Proximity to World-Class Engineering Experts for Photonic Computing and Optical AI Inference InitiativeJuly 1, 2026 | globenewswire.comYour book attachedBill Poulos is giving away his 'Simple Options Trading For Beginners' book at no cost - normally $29.97. It outlines the approach he developed after losing a small fortune on complex strategies. The book covers a straightforward technique that he says consistently outperforms complicated methods, including how to evaluate any trade in under 10 minutes.August 4 at 1:00 AM | Profits Run (Ad)Q/C Technologies Relocates Headquarters to San Francisco in Proximity to World-Class Engineering Experts for Photonic Computing and Optical AI Inference InitiativeJune 30, 2026 | globenewswire.comSee More Headlines QCLS Stock Analysis - Frequently Asked Questions How have QCLS shares performed this year? Mymd Pharmaceuticals' stock was trading at $4.33 on May 15, 2026. Since then, QCLS stock has decreased by 32.4% and is now trading at $2.9250. How were Mymd Pharmaceuticals' earnings last quarter? Mymd Pharmaceuticals, Inc. (NASDAQ:QCLS) issued its earnings results on Friday, May, 15th. The company reported ($0.19) EPS for the quarter. How do I buy shares of Mymd Pharmaceuticals? Shares of QCLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings5/15/2026Today8/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1w+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 For the last 7 days, QCLS's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorTechnology Industry Technology Hardware, Storage & Peripherals Sub-IndustryTechnology Hardware, Storage & Peripherals Current SymbolNASDAQ:QCLS CIK1321834 WebN/A Phone(856) 848-8698Fax856-848-0269Employees6Year FoundedN/AProfitability EPS (Trailing Twelve Months)($20.69) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$11.63 million Net MarginsN/A Pretax MarginN/A Return on Equity-76.40% Return on Assets-35.10% Debt Debt-to-Equity RatioN/A Current Ratio3.72 Quick Ratio3.72 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.19 per share Price / Book0.55Miscellaneous Outstanding Shares4,170,000Free Float4,131,000Market Cap$11.97 million OptionableN/A Beta2.16 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:QCLS) was last updated on 8/4/2026 by MarketBeat.com Staff. From Our PartnersPass by August 7… or wait until 2027?A ruling just came down that most investors haven't connected to crypto yet. Chatrie v. United States — the...Crypto 101 Media | Sponsored7 Bankers Met in Secret (Now We Pay for It)A little-known meeting in 1910 cost the average American family their entire financial freedom. They met in se...Decentralized Masters | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredThe Market Hasn't Fully Caught This YetSurface samples on this project have returned grades up to 73 g/t gold and 21% copper, right next to a produce...i2i Marketing Group, LLC | SponsoredApple just sent a powerful signal to investorsApple just crossed a $5 trillion market value as shares climbed 25% this year, fueled by new product launches ...Mode Mobile | SponsoredYour book attachedBill Poulos is giving away his 'Simple Options Trading For Beginners' book at no cost - normally $29.97. It ou...Profits Run | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mymd Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mymd Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
